HAS Healthcare Advanced Synthesis to Acquire Cerbios-Pharma

• HAS Healthcare Advanced Synthesis SA has announced the planned acquisition of Cerbios-Pharma SA, expanding its presence in the pharmaceutical contract development and manufacturing sector.

• The deal is supported by 65 Equity Partners, which will acquire a 40% stake, while the Braglia family retains majority ownership.

HAS Healthcare Advanced Synthesis SA (HAS) has announced its acquisition of Cerbios-Pharma SA (Cerbios), a Switzerland-based manufacturer of chemical and biological active pharmaceutical ingredients (APIs). The transaction aims to enhance HAS’s capabilities in high-potency APIs and antibody-drug conjugates (ADCs), further solidifying its position as a key player in the contract development and manufacturing (CDMO) industry.

The acquisition is backed by 65 Equity Partners, a global investment firm supporting family-owned businesses. As part of the agreement, 65 Equity Partners will acquire approximately 40% of HAS, while the Braglia family retains majority ownership. Both HAS and Cerbios will continue to operate under their existing corporate culture and values, with a commitment to Switzerland’s Ticino region.

The integration of HAS and Cerbios is expected to create a more comprehensive pharmaceutical manufacturing platform, combining chemical and biological expertise. The companies will serve global pharmaceutical clients across therapeutic areas, including oncology, neurology, endocrinology, dermatology, and rare diseases.

Riccardo Braglia, CEO of 3B Future Holding SA and board member of HAS, described the acquisition as a major step in HAS’s global expansion strategy. “By merging complementary skills and resources, we are confident that we can provide our clients with innovative, personalized, and high-quality solutions,” he said. Christian Suà, CEO of Cerbios, highlighted that the merger will accelerate growth and enhance the company’s service offerings.

Pascal Heberling, Partner and Co-Head of Europe at 65 Equity Partners, expressed enthusiasm about the collaboration with the Braglia family, stating, “We are pleased to unite two highly complementary businesses that have earned the trust of leading pharmaceutical companies worldwide. The industry continues to experience robust structural growth, driven by demographic shifts, scientific advancements, and increasing demand for advanced therapies. These factors make it both an attractive and resilient sector in the long run.”

Waldo Mossi, CEO of HAS Healthcare Advanced Synthesis SA, highlighted the strategic nature of the transaction: “This partnership has been in the works for some time, with the goal of establishing a key chemical-pharmaceutical hub in Ticino. By combining our distinct pipelines and client bases, we will achieve new milestones and enhance the quality of services we provide. This joint effort strengthens our market position and reinforces both companies’ commitment to innovation. Additionally, we are bringing together a workforce of over 400 employees, who will be instrumental in shaping this new venture. We deeply appreciate their dedication and look forward to a future of continued growth and innovation.”

Christian Suà, CEO of Cerbios-Pharma SA, emphasized the benefits of the merger, stating, “Joining HAS Healthcare Advanced Synthesis SA marks a significant step forward for us, allowing us to contribute to the strength and expansion of the new Group. HAS is the perfect partner to accelerate our growth, broaden our service offerings, and enhance the value we deliver to our clients.”